
CLAIMS

1. Use of ~~A~~a compound of General Formula (I)



in which:

X1 represents a halogen, a R1, or G1-R1 group;

A represents a CH=CH or a CH2-CH2 group;

X2 represents a G2-R2 group;

G1 and G2, identical or different, represent an atom of oxygen or sulfur;

R1 represents a hydrogen atom, an unsubstituted alkyl group, an aryl group or an alkyl group that is substituted by one or more halogen atoms, an alkoxy or an alkylthio group, cycloalkyl groups, cycloalkylthio groups or heterocyclic groups;

R2 represents an alkyl group substituted by at least a –COOR3 group, wherein R3 represents a hydrogen atom, or an alkyl group that is substituted or not by one or more halogen atoms, cycloalkyl groups, or heterocyclic groups.

R4 and R5, identical or different, representing an alkyl group that is substituted or not by one or more halogen atoms, cycloalkyl groups, heterocyclic groups;

in the manufacture of a medicament for ~~use in a method for the~~ treating~~ment~~ of liver disorders.

2. The ~~compound~~ use of claim 1 wherein the compound is of general formula (I) in which:

X1 represents a halogen, a R1, or a G1-R1 group;

A represents a CH=CH group;

X2 represents a G2-R2 group;

G1 and G2, identical or different, represent an atom of oxygen or sulfur;

R1 represents an alkyl or cycloalkyl group having from one to seven carbon atoms, in particular, the alkyl or cycloalkyl group being substituted or not by one or more halogen atoms;

R2 represents an alkyl group substituted by a –COOR3 group, wherein R3 represents a hydrogen atom or an alkyl group having from one to four carbon atoms.

R4 and R5 represent an alkyl group having from one to four carbon atoms.

3. The ~~compound~~ use of claim 1 wherein the compound is of general formula (I) in which:

X1 represents a R1 or G1-R1 group;

A represents a CH2-CH2 group;

X2 represents a G2-R2 group;

G1 represents an atom of oxygen or sulfur and G2 represents an atom of oxygen;

R1 represents an alkyl or cycloalkyl group having from one to seven carbon atoms;

R2 represents an alkyl group substituted by at least a –COOR3 group, wherein R3 represents a hydrogen atom or an alkyl group having from one to four carbon atoms;

R4 and R5 represent an alkyl group having from one to four carbon atoms.

4. The ~~compound~~ use of claim 1 wherein the compound is of general formula (I) in which:

X1 represents a halogen atom or a R1 or G1-R1 group;

A represents a CH2-CH2 group;

X2 represents a G2-R2 group;

G1 represents an atom of oxygen or sulfur and G2 represents an atom of oxygen;

R1 represents an alkyl or cycloalkyl group that is substituted by one or more halogen atoms;

R2 represents an alkyl group substituted or not by one or more halogen atoms and substituted by at least a –COOR3 group, wherein R3 represents a hydrogen atom or an alkyl group having from one to four carbon atoms.

R4 and R5 represent an alkyl group having from one to four carbon atoms.

5. The ~~compound~~ use of any one of the preceding claims, wherein G2 is an oxygen atom and R2 is an alkyl group substituted by a –COOR3 group, wherein R3 represents a hydrogen atom or an unsubstituted linear or branched alkyl group having from one to four carbon atoms.

6. The ~~compound~~ use of any one of the preceding claims wherein X1 is an alkylthio group that comprises an alkyl group that is linear or branched, having from one to seven carbon atoms that is substituted or not by one or more halogen atoms.

7 The ~~compound~~ use of any one of the preceding claims, wherein said compound is selected in the group consisting of 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxy phenyl]prop-2-en-1-one, 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-isopropyloxy carbonyldimethylmethyloxyphenyl]prop-2-en-1-one, 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-tertbutyloxycarbonyldimethylmethyloxyphenyl] prop-2-en-1-one, 1-[4-trifluoromethylphenyl]-3-[3,5-dimethyl-4-tertbutyloxycarbonyl dimethylmethyloxyphenyl]prop-2-en-1-one, 1-[4-trifluoromethylphenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one, 1-[4-trifluoromethyl oxyphenyl]-3-[3,5-dimethyl-4-tertbutyloxycarbonyldimethylmethyloxy phenyl] prop-2-en-1-one, 1-[4-trifluoromethyloxyphenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyl oxyphenyl]prop-2-en-1-one, 2-[2,6-dimethyl-4-[3-[4-(methylthio)phenyl]-3-oxo-propyl] phenoxy]-2-methylpropanoic acid, and 2-[2,6-dimethyl-4-[3-[4-(methylthio) phenyl]-3-oxo-propyl]phenoxy]-2-methyl-propanoic acid isopropyl ester.

8. The ~~compound~~ use of any one of the preceding claims, wherein the ~~compound~~ medicament is to be administered in combination with metformin, insulin, thiazolidinediones, glitazones, or statins.

9. Use of ~~A~~a pharmaceutical composition comprising a compound of General Formula (I) as defined in any one of claims 1 to 8, in the manufacture of a medicament for ~~use in a method for the~~ treating~~ment of~~ liver disorders.

10. The ~~pharmaceutical composition~~use of claim 9, wherein said pharmaceutical composition is formulated in the form of injectable suspensions, gels, oils, pills, suppositories, powders, gel caps, capsules, aerosols or means of galenic forms or devices assuring a prolonged and/or slow release.

11. The ~~compound~~ use of any one of claims 1 to ~~8 or the pharmaceutical composition of claim 9 or~~ 10, ~~for use in a method for the treatment of a~~wherein the liver disorder is selected ~~in~~ from the group consisting of liver fibrosis, a fatty liver disease, and non-alcoholic steatohepatitis.